It all begins with an idea.

To design a tool for surgical explant of endografts.

Consider; 80% of AAA patients receive EVAR, the minimally invasive option for repair. Getting a quality result quickly and efficiently is most assuredly part of the goal for both the patient and physician. At some point, 5+% of EVAR grafts are explanted due to failure or infection.

Our goal: develop a simple device for open surgical explant of an endovascular stent graft.  At Hjärta Care we believe minimally invasive surgery should not just be the goal at implant. We believe the explant should be as atraumatic and painless as possible for both the patient and vascular surgeon. We discovered, through interviews and search of the clinical literature, that the syringe technique, orthopedic wire cutters, etc. were woefully inadequate in achieving a SAFE explant. In 2022 Hjärta Care received a patent for the XgraftR, a tool specifically designed for the removal of endovascular stent grafts during open surgical explant. This unique patented design allows for a simple and elegant explant, minimizing supra visceral cross clamp time and damage to the aortic intima.

Quality Policy

Hjärta Care manufactures and distributes a tool for the simple, atraumatic, fast, and elegant explant of failed endografts. HjärtaCare shall ensure that its product is manufactured to the highest standards, and that the needs of its customers are consistently met or exceeded. HjärtaCare shall ensure the quality of its product through the application of a fully compliant Quality Management System (QMS), and through its partnership with skilled and experienced suppliers.